
usd jan pm et
summari maker radiotherapi cancer system also suppli x-ray tube flat-panel digit
subsystem imag medic scientif industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
dec pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep sell
system inc lift target
price reflect multipl
ep var
averag
metric cash flow dec-q ep vs
fell short consensu chang
fy sep ep
fy ep dec-q
million in-lin expect
oncolog order grew gross order
america increas emea apac
flow oper cffo
million quarter yoy due
invest work capit past
two fiscal year quarterli cffo
highest dec-q case fy
lower cffo guidanc
base press releas work capit
trend appear deterior backlog
coverag rel one-year forward revenu
declin yoy maintain sell
larg establish custom base
equip servic high switch cost
addit compani typic maintain net
cash posit gener posit free cash flow
hand industri cancer treatment
highli competit character technolog
innov new product entrant although radiat
therapi like continu integr compon
global cancer treatment protocol continu
develop drug-bas oncolog treatment
repres substanti threat compani
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice-president financ
senior vice presid
corpor overview varian world lead manufactur medic devic softwar
treat cancer medic condit radiotherapi stereotact radiosurgeri
stereotact bodi radiotherapi brachytherapi proton therapi oper group two
report oper segment oncolog system proton solut oncolog system repres
bulk revenu segment made total revenu fiscal year
sep respect
market profil driven age global popul improv diagnost method number
newli diagnos cancer case continu increas number new cancer case diagnos annual
project increas almost million million accord
radiat therapi commonli use treatment cancer alon combin surgeri
chemotherapi immunotherapi target drug use radiat treat cardiac diseas
gain interest medic commun current investig clinic trial set
common type radiotherapi use x-ray deliv extern beam administ use
linear acceler addit extern radiat radioact seed wire ribbon sometim
insert tumor bodi caviti brachytherapi modal requir radiat
pass healthi tissu
varian oncolog system busi design manufactur sell servic hardwar softwar
product treat cancer convent radiotherapi advanc treatment fix field
sbrt brachytherapi
proton solut busi develop design manufactur sell servic product system
deliv proton therapi anoth form extern beam radiotherapi use proton beam
treatment cancer although proton therapi clinic use four decad
wide deploy due high capit cost var current focu improv proton therapi
clinic util reduc cost treatment per patient wide accept
deploy therapi thought especi use pediatr case larg tumor ocular
tumor tumor adjac sensit healthi tissu
major develop juli may trump administr impos seri
tariff rang numer product import china includ var
radiotherapi system manufactur china certain compon use var manufactur
servic activ juli august china retali tariff impos
seri tariff rang certain product import china includ
radiotherapi system certain manufactur servic compon request tariff
exclus chines tariff grant exclus
also made sever tuck-in acquisit includ endocar cancer treatment
servic asset acquisit follow var
attempt acquir sirtex medic limit manufactur target radioact treatment liver
cancer billion howev sirtex receiv stronger counteroff outbid
quarter end decemb divest former imag compon busi varex
imag corpor quarter also absorb ginzton technolog center busi
previous reflect oncolog system busi
competit landscap market radiat therapi equip softwar character
rapidly-evolv technolog intens competit price pressur view radiotherapi
radiosurgeri market primarili compet elekta ab accuray incorpor addit
elekta ab viewray incorpor introduc mr-linac devic also compet
hospit budget alloc varieti competitor offer qualiti
assur product mobiu qumul patient monitor track product humediq
product line inform imag manag offer
addit substanti amount resourc invest research develop new
therapi cancer success develop altern therapi cancer
immunotherapi increas efficaci new therapi exist product price decis
competitor rate market penetr competit product may render var product
obsolet noncompetit
financi trend fy sep revenu grew billion billion fy adjust
ep fy repres increas prior year five-year compound annual
growth rate compound-annual-growth-rate adjust ep fy approxim recent year compani
tend maintain net cash posit posit free cash flow defin cash flow oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc octob technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
cost site delay proton solut busi lower sep
ep maintain ep mar-q sale increas
constant currenc million oncolog order
constant currenc order america increas emea apac
sale apac region driven acceler growth
china despit manag revenu guidanc rais think
revenu growth could pressur unfavor work capit trend
mar-q receiv day dso increas year-over-year defer
revenu day dsdr decreas trend hint possibl slowdown
et cfra lower opinion share varian medic system inc
sell hold share risen year-to-d
push beyond price target valuat repres forward
price-to-earnings ratio forward earn estim ratio high-end
three-year forward price-to-earnings rang like buoy
recent optim expect roughli half futur revenu growth
tie market outsid market could pressur
gener slow global econom activ believ share
trade fair valu especi given recent deterior work
receiv depress current defer revenu well chines tariff
concern process request grant tariff
exclus china lower price target
reflect forward price-to-earnings multipl three-year averag
analyst research note compani news
et cfra keep sell opinion share varian medic system
inc lift target price reflect multipl
ep var averag
concern regard var work capit metric
cash flow dec-q ep vs fell short consensu
chang fy sep ep fy ep
dec-q sale increas constant currenc million
in-lin expect oncolog order grew gross order
america increas emea apac flow oper cffo
million quarter yoy due invest work
capit past two fiscal year quarterli cffo highest
dec-q case fy lower cffo guidanc
base press releas work capit trend appear deterior
backlog coverag rel one-year forward revenu declin yoy
maintain sell rate /kevin huang cfa
et cfra keep sell opinion share varian medic system
inc lift target price reflect multipl
ep averag
concern regard work capit metric cash flow
sour global econom outlook sep-q ep vs fell
short expect lift fy sep ep
initi fy ep sep-q sale increas constant
currenc million oncolog order grew report
constant currenc basi america order grew emea apac
order decreas continu soft apac primarili relat
japan partial off-set growth china south east asia korea
concern cash flow outlook million actual
fy cash flow oper cffo fell significantli short
recent guidanc million higher work capit
support product transit growth /kevin huang cfa
et cfra reiter sell opinion share varian medic
system inc despit improv -china trade tension
chines tariff exempt medic linear acceler remain
concern recent deterior work capit metric
gener sour global econom outlook also believ propos
new bundl payment model radiat oncolog therapi could hurt
profit expect provid commentari payment model
sep earn call lower target price
reflect forward price-to-earnings multipl fy ep estim
et cfra keep sell opinion share varian medic system
inc lower target price reflect multipl
ep near averag
jun-q ep vs significantli exceed consensu expect
yet narrow full-year ep guidanc point higher
interest expens invest sg spend cost
driver lower fy sep ep fy ep
jun-q sale increas constant currenc
million oncolog order grew constant currenc order
america decreas emea increas apac decreas despit
soft across apac china double-digit unspecifi growth us-china
tariff neg impact earn million quarter despit
receiv three new order proton solut segment total
million took million impair charg proton busi
et cfra reiter sell opinion share varian medic
system inc lower target reflect
multipl ep near averag
mar-q ep vs lower estim
stronger-than-expect impact tariff addit increas project
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
